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Efavirenz resistance during HIV-1 treatment failure is usually associated with the reverse transcriptase mutation K103N. L100I, V108I, or
P225H can emerge after K103N and increase its level of efavirenz resistance. K103N + L100I is the most drug-resistant of the double mutants but
is the least common clinically. We hypothesized that differences in replication efficiency, or fitness, influence the relative frequencies of these
secondary efavirenz resistance mutations in clinical isolates. We measured fitness of each secondary mutant introduced into HIVNL4-3, alone and in
combination with K103N, using growth competition assays in H9 cells. In the absence of efavirenz, the fitness of V108I was indistinguishable
from wild type. K103N, L100I, and P225H were minimally, but consistently, less fit than wild type. K103N + L100I had a greater reduction in
fitness and was less fit than K103N + V108I and K103N + P225H. The fitness defect of K103N + L100I relative to K103N was completely
compensated for by the addition of the nucleoside resistance mutation L74V. In the presence of efavirenz, L100I was less fit than K103N, and
K103N + L100I was more fit than K103N + V108I. Our studies suggest the primary driving force behind the selection of secondary efavirenz
resistance mutations is the acquisition of higher levels of drug resistance, but the specific secondary mutations to emerge are those with the least
cost in terms of replication efficiency. In addition, nucleoside and NNRTI resistance mutations can interact to affect HIV replication efficiency;
these interactions may influence which mutations emerge during treatment failure. These studies have important implications for the design of
more durable NNRTI–nucleoside combination regimens.
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Efavirenz is a non-nucleoside reverse transcriptase inhibitor
(NNRTI) that is recommended, in combination with two
nucleoside analogs, for the treatment of HIV-1 infected
individuals who are antiretroviral-naive (DHHS, 2005; Yeni et
al., 2004). Although efavirenz is highly effective when used in
this setting, efavirenz-resistant mutants of HIV-1 commonly⁎ Corresponding author. Department of Medicine, University of Rochester
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doi:10.1016/j.virol.2006.05.021develop if virologic failure occurs. The reverse transcriptase
mutation K103N is the most common resistance mutation that
emerges in patients failing efavirenz-containing antiretroviral
regimens and confers cross-resistance to the two other available
NNRTIs, nevirapine and delavirdine (Bacheler et al., 2000,
2001).
After the emergence of K103N during efavirenz treatment
failure, secondary mutations (L100I, V108I, and P225H) can
develop that augment the efavirenz resistance of K103N
(Bacheler et al., 2000). However, the degree of drug resistance
conferred by these secondary resistance mutations does not
uniformly predict their relative frequencies in clinical isolates
during treatment failure. In early studies of efavirenz,
Fig. 1. Correlation between quantification of mutant prevalence by direct
sequencing of PCR product versus clonal analysis. Results from five
independent growth competition assays using the L100I, K103N, V108I,
P225H, or P236L mutants were pooled for use in this analysis. The same PCR
amplified product was either directly sequenced or cloned into a bacterial
plasmid and transformed into E. coli, with subsequent sequence analysis of
DNA isolated from each clone. Twenty-four consecutive, unselected clonal
sequences were utilized for each determination. The results of one assay were
not known when analyzing the results of the other assay.
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double mutants, each occurring in approximately 30–40% of
resistant isolates, with K103N + L100I occurring in approxi-
mately 10% (Bacheler et al., 2000). When placed into the
laboratory strain HIVNL4-3, secondary mutations increase the
efavirenz IC90 of K103N. However, the relatively uncommon
genotype K103N + L100I confers approximately 25- to 30-fold
more efavirenz resistance than the more common genotypes
K103N + V108I or K103N + P225H (Bacheler et al., 2001).
Our previous work with primary resistance mutations to
nevirapine, delavirdine, and efavirenz found that mutants
which confer significant drug resistance but develop uncom-
monly during virologic failure in patients have significant
reductions in replication fitness, as measured by growth
competition assays in T cell lines (Archer et al., 2000;
Gerondelis et al., 1999; Wang et al., 2006). These differences
in relative replication efficiency would presumably affect the
relative prevalence of these mutants before therapy is initiated
(Coffin, 1995) and could reduce the chance that these mutants
would emerge in patients during drug therapy. In addition, we
found that less-fit mutants with modest (2- to 3-fold) increases
in drug resistance still were outgrown by the more-fit, less drug-
resistant K103N mutant in the presence of drug (Gerondelis
et al., 1999; Wang et al., 2006). We therefore hypothesized that
differences in relative replication efficiency could account for
the lower than expected frequency of the K103N + L100I
double mutant in clinical isolates.
To determine whether fitness differences could account for
the relative prevalence of efavirenz resistance mutations in
clinical isolates, we performed competition experiments in the
absence of drug between a wild-type laboratory strain of HIV-
1 and the site-directed mutants L100I, V108I and P225H,
alone and in combination with K103N. Because of observa-
tions that K103N + L100I was frequently associated with the
nucleoside resistance mutation L74V (Ait-Khaled et al., 2003;
Demeter et al., 2004), we also determined the effect of L74V
on the fitness of K103N + L100I. We then performed selected
competition experiments in the presence of efavirenz to
determine how the presence of drug affects these fitness
differences.
Results
Relative fitness of L100I, K103N, V108I, and P225H in the
absence of efavirenz
Before evaluating the impact of the secondary efavirenz
resistance mutations L100I, V108I, and P225H on the relative
fitness of K103N, we first tested the effects of each of these
mutations individually on HIV-1 replication fitness. We
introduced each mutation separately into pNL4-3, using
PCR-mediated site-directed mutagenesis, and produced virus
stocks by transfecting each plasmid separately into 293 cells.
Using a CD4-negative cell line for transfection minimizes the
likelihood that extraneous mutations would be introduced
during reverse transcription, since progeny virus cannot infect
the cells. For comparison, we also produced a virus stockfrom pNL4-3 containing the delavirdine-resistant P236L
mutation, which we have shown has reduced replication
efficiency (Gerondelis et al., 1999). We then evaluated the
relative fitness or replication efficiency of these mutants by
co-infecting the H9 lymphoid cell line with each mutant in
combination with wild-type NL4-3. These infections were
performed at a low ratio of virus to cells, to minimize the
chances of cells being co-infected by both variants. Under
these conditions, the relative replication efficiency or fitness
of each mutant can then be directly compared to wild-type
virus in the same culture, by monitoring the change in relative
prevalence of the mutant variant over time, using direct
sequence analysis of PCR-amplified proviral DNA. We have
used this approach successfully in previous studies to evaluate
the relative fitness of other NNRTI-resistant variants (Archer
et al., 2000; Wang et al., 2006).
Clonal analysis is generally considered to be more accurate
than direct sequencing of PCR-amplified products for the
quantification of minority viral variants but is labor-intensive.
We reasoned that direct sequence analysis of bulk PCR product
would give similar results to clonal analysis in our growth
competition assays, since we were using site-directed mutant
viruses that differed only in the specific mutation being
examined. Thus, variation in surrounding nucleotide sequence,
which can influence efficiency of amplification during PCR or
specificity of fluorescent-labeled terminator incorporation
during the sequencing reaction, would not be present to
complicate our assessment of the prevalence of a given mutant.
In addition, we took the added precaution of averaging the
relative peak heights for a mutant base from both sense and
antisense primers that were within 300 nucleotides of the codon
being assayed. To verify the concordance between bulk
186 C.E. Koval et al. / Virology 353 (2006) 184–192sequencing and clonal analysis, we compared the ratio of
mutant virus for each mutant codon at selected time points using
bulk sequence analysis with the ratio derived by clonal analysis.
Analysis of 24 consecutive, unselected clonal sequences from atFig. 2. Growth competition assays between efavirenz-resistant and wild-type NL4-3,
each case is wild-type NL4-3. (A) K103N. (B) V108I. (C) P225H. (D) L100I. (E) Pleast one growth competition experiment per mutant verified
that the measurement of peak heights at each mutant base
correlates well with estimates of mutant proportions using
clonal analysis (Fig. 1).inoculated at a ratio of 1:1, based on p24 antigen content. The reference strain in
236L.
Fig. 3. Growth competition assays between K103N and L100I, in the absence
and presence of efavirenz. The L100I and K103N variants were inoculated at a
ratio of 1:1, based on p24 antigen content. Solid lines, proportion of K103N,
measured by direct sequence analysis at codon 103. Dotted lines, proportion of
L100I, inferred from sequence analysis at codon 103. The same results were
obtained when the prevalence of L100I was measured directly by sequence
analysis at codon 100 (data not shown).♦, No efavirenz;▪, 10 nM efavirenz;▴,
100 nM efavirenz; •, 1 μM efavirenz.
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of efavirenz, we found that the K103N mutant has a modest
but consistent fitness defect, compared to wild-type NL4-3
(Fig. 2A). Similar to K103N, the other secondary efavirenz
resistance mutations had minor adverse effects on replication
fitness, particularly when compared with P236L. Although
wild-type virus clearly has an advantage over K103N, P225H,
and L100I, these mutants still persist at moderate levels after 2
weeks in culture (Figs. 2A, C, D), whereas the P236L mutant
is completely overgrown by day 11 (Fig. 2E). Under the
conditions we used, we were unable to detect a reliable
reduction in fitness of the V108I mutant relative to wild-type
virus over a 2-week time period (Fig. 2B).
It appeared from the statistical analysis of relative fitness
values that V108I and P225H were more fit than L100I or
K103N (Table 1). In order to experimentally verify the
existence of these small differences in relative fitness values,
we directly competed these single mutants against each other in
growth competition experiments. These direct comparisons
established a hierarchy of relative fitness of V108I > P225H >
K103N ∼L100I (data not shown), although the magnitude of
these fitness differences is modest, and takes 2–3 weeks to
detect in culture.
These findings are compatible with the observation that
K103N is commonly selected for during clinical failure of
NNRTIs, even though K103N confers only moderate levels of
NNRTI resistance. We have proposed that larger deficits in
fitness, such as those seen with the V106A, G190S and P236L
mutants, can retard or prevent the emergence of an NNRTI-
resistant variant during therapy (Archer et al., 2000; Geronde-
lis et al., 1999; Wang et al., 2006). V108I and P225H confer
minimal levels of efavirenz resistance by themselves (fold
changes in IC90 of 1.6- and 1.2-fold, respectively, compared to
wild-type virus) (Bacheler et al., 2001), and this lack of
resistance is presumably the reason why these highly fit
mutants are rarely seen in the absence of K103N (Bacheler
et al., 2000).Table 1
Relative fitness values of NL4-3 virus containing site-directed single efavirenz
resistance mutations compared to wild type NL4-3




K103N 10 0.94 0.03 <0.0001
L100I 7 0.93 0.03 0.0007
V108I 6 0.99 0.01 NSd
P225H 6 0.96 0.02 0.01
P236L 4 0.60 0.06 0.001
a Results shown are means of replicate assays.
b s = ln[(Mt /M0)/(Rt /R0)] /t; t is the time after co-infection, Rt is the proportion
of reference strain at time t, Mt is the proportion of mutant at time t, R0 is the
proportion of reference strain at time 0,M0 is the proportion of mutant at time 0
(Holland et al., 1991).
c t Test for comparisons of (1 + s) value for each mutant and the reference
strain.
d NS, not significant, P > 0.05.Fitness of L100I compared to K103N in the presence of
efavirenz
The assay we used to measure replication fitness did not
detect a major reduction in fitness of the L100I mutant,
which is uncommon clinically despite having a similar level
of efavirenz resistance to K103N, as measured with
traditional drug susceptibility assays (Bacheler et al., 2001;
Petropoulos et al., 2000). Thus, relative fitness, as measured
in this assay, does not explain the much more frequent
occurrence clinically of K103N compared to L100I
(Bacheler et al., 2000). In order to assess how the presence
of efavirenz affected the relative fitness of these two
mutants, we performed growth competition experiments in
the presence of different concentrations of efavirenz (Fig.
3). We found that, although K103N has a similar fitness
compared to L100I in the absence of efavirenz, the K103N
mutant rapidly outgrows the L100I mutant in the presence
of both 10 nM and 100 nM efavirenz (Fig. 3). In the
presence of 1 μM efavirenz, there was little virus growth,
and we were unable to amplify PCR product at timepoints
later than 7 days after infection. In order to verify the
published efavirenz susceptibilities of the L100I and K103N
mutants, we performed a modification of a previously
published drug susceptibility assay (Japour et al., 1993),
using H9 cells instead of human peripheral blood
mononuclear cells (PBMCs). These studies demonstrated
similar efavirenz IC50 values for K103N (6.5 nM) and
L100I (5.3 nM).
Fig. 4. Growth competition assay between K103N + L100I and K103N + V108I
in the absence and presence of efavirenz. Mutant viruses were inoculated at a
ratio of 1:1, based on p24 antigen content. Results represent the aver-
age ± standard error of the mean of at least three independent experiments. Solid
lines, prevalence of K103N + V108I, based on sequence analysis at codon 108.
Dotted lines, inferred prevalence of K103N + L100I, based on sequence analysis
at codon 108. Sequence analysis at codon 100 gave the same results (data not
shown). ⋄, No efavirenz; ▵, 100 nM efavirenz; ○, 1 μM efavirenz, ×, 10 μM
efavirenz.
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P225H compared to K103N in the absence of efavirenz
We next compared the effects of the secondary efavirenz
resistance mutations L100I, V108I, and P225H on the
relative replication fitness of K103N in the absence of
efavirenz. We found that both V108I and P225H have
minimal adverse effects on the replication fitness of K103N
(Table 2). Therefore, these secondary mutations substan-
tially augment the efavirenz resistance of K103N with little
cost in terms of replication fitness. In contrast, a more
substantial fitness impairment is seen with K103N + L100I
relative to K103N (Table 2). This fitness impairment may
explain why K103N + L100I is seen less commonly than
K103N + P225H and K103N + V108I in some studies of re-
sistance during efavirenz treatment failures (Bacheler et al.,
2000).
To directly verify the fitness differences seen when these
mutants were compared to K103N, we performed pairwise
growth competitions between each of these double mutants
and found that K103N + V108I is substantially more fit
than K103N + L100I (1 + s = 1.322 [SD 0.16]) and somewhat
less fit than K103N + P225H (1 + s = 0.94 [SD 0.031]). These
data support a relative fitness hierarchy of K103N ~_K103N +
P225H > K103N + V108I > K103N + L100I.
Fitness of K103N + L100I compared to K103N + V108I and
K103N in the presence of efavirenz
We also evaluated the relative fitness of K103N + L100I
and K103N + V108I in the presence of efavirenz, in order
to determine whether escalating concentrations of efavirenz
could overcome the replication defect of the more drug-
resistant K103N + L100I mutant. Growth competition assays
between K103N + V108I and K103N + L100I demonstrated
that K103N + L100I was more fit than the K103N + V108I
mutant at 100 nM efavirenz, and that this improved fitness
persisted at higher drug concentrations (Fig. 4). We also
found similar results when comparing the relative fitness of
K103N + L100I to K103N in the presence and absence οf
efavirenz (data not shown).Table 2
Relative fitness values of NL4-3 with site-directed double efavirenz resistance
mutations compared to NL4-3 virus containing K103N alone
No. replicates 1 + s a, b SD P value c
K103N (reference) 1
K103N + L100I 8 0.84 0.01 <0.0001
K103N + V108I 8 0.92 0.02 0.03
K103N + P225H 8 0.99 0.01 NSd
a Results shown are means of replicate assays.
b s = ln[(Mt /M0) /(Rt /R0)] /t, t is the time after co-infection, Rt is the proportion
of reference strain at time t, Mt is the proportion of mutant at time t, R0 is the
proportion of reference strain at time 0,M0 is the proportion of mutant at time 0
(Holland et al., 1991).
c t Test for comparisons of (1 + s) value for each mutant and the reference
strain.
d NS, not significant, P > 0.05.Effect of the nucleoside resistance mutation L74V on the
relative fitness of K103N + L100I
We had noted an apparent association of L74V with
K103N + L100I in two studies of efavirenz combination therapy
in highly treatment experienced patients (Ait-Khaled et al.,
2003; Demeter et al., 2004). We tested the hypothesis that L74VFig. 5. Growth competition assay between K103N + L100I and K103N +
L100I + L74V (inoculated at a 75:25 ratio, respectively, based on p24 antigen
content) in the absence of efavirenz. Results represent the average ± standard error
of the mean of at least three independent experiments.
189C.E. Koval et al. / Virology 353 (2006) 184–192might improve the replication capacity of K103N + L100I, by
performing growth competition assays using the double and
triple mutants. We found that in the absence of drug,
K103N + L100I + L74V was substantially more fit than
K103N + L100I, 1 + s = 1.21 (SD 0.03) (Fig. 5). Direct com-
petitions of the K103N + L100I + L74V triple mutant with
K103N demonstrated no detectable differences in replication
capacity (1 + s = 1.01 [SD 0.05]), suggesting that L74V fully
compensates for the fitness reduction conferred by L100I when
combined with K103N. Growth competition assays in the
presence of efavirenz (100 nM–10 μM) demonstrated no
significant increase in efavirenz resistance of the triple mutant
relative to K103N + L100I (data not shown).
Discussion
Our studies support the hypothesis that differences in
replication capacity influence the frequency with which
specific NNRTI resistance mutations occur in clinical isolates.
K103N, the most commonly reported mutant, has only a
minor reduction in replication efficiency, that is substantially
less than those we have measured for other, less common
NNRTI-resistant variants, such as V106A, P236L, and G190S
(Archer et al., 2000; Gerondelis et al., 1999; Wang et al.,
2006). Reductions in replication efficiency also appear to
explain the less frequent occurrence in most studies of the
highly resistant K103N + L100I double mutant, relative to
K103N + V108I and K103N + P225H.
Our studies do have limitations, and our data should be
interpreted with some caution. Our data were generated using
site-directed mutants of NL4-3, a laboratory strain of HIV-1.
Since mutations arise clinically in the context of polymorphisms
and background mutations in reverse transcriptase, we cannot
be certain whether the fitness effects of mutations in NL4-3 can
fully explain their frequency in patient isolates. Studies that
describe fitness effects of these mutations within the genetic
backbone of clinical isolates may be more clinically relevant.
Additionally, we used H9 cells rather than PBMCs in our
competition experiments. It is possible that fitness differences
might be affected by cellular factors involved in viral replication
such as dNTP concentration and that the PBMCs may better
reflect the effect of mutations on viral replication in patients.
However, our studies in which fitness of NNRTI-resistant
variants was measured both in cell lines and in PBMCs did not
show substantial differences in results (Gerondelis et al., 1999).
One would expect the most differences in relative fitness
between PBMCs and cell lines for mutants that affect affinity
for nucleotides, such as the M184V mutant (Back et al., 1996).
Our biochemical studies have not to date identified such
abnormalities in NNRTI-resistant variants (Domaoal et al., in
press; Wang et al., 2006).
Finally, the clinical relevance of competitions in the presence
of efavirenz should be interpreted with caution. Efavirenz is
highly protein bound in patients, and it is difficult to extrapolate
specific concentrations in cell culture (in the presence of only
20% serum) to the clinical setting. Thus, our observations
concerning the changes in relative fitness of mutants in thepresence of efavirenz indicate general trends but do not
necessarily indicate that these specific efavirenz concentrations
will be associated with the same mutation prevalence in treated
patients.
We speculate that there is a significant fitness cost associated
with very high levels of NNRTI resistance, and that it is difficult
to select a single mutant that is highly fit and highly NNRTI-
resistant. It seems plausible that a mutation with large effects on
drug binding may sufficiently distort the structure of the
surrounding region, leading to greater dysfunction of the
reverse transcriptase, with concomitantly greater reductions in
replication efficiency. This correlation between increased
NNRTI resistance and decreased replication capacity was
observed in a recent study of mutations at codon 190, using a
single cycle replication assay (Huang et al., 2003). Similar
observations have also been made for mutations conferring
resistance to the fusion inhibitor, enfuvirtide (Lu et al., 2004).
Thus, the frequent initial selection for K103N in clinical
samples may reflect the fact that it has an optimal balance
between replication efficiency and drug resistance, at least to
currently available NNRTIs.
Higher levels of efavirenz resistance are instead achieved
through the selection of secondary resistance mutations, usually
those at V108I and P225H. These mutations by themselves
confer little, if any efavirenz resistance, and minimal reductions
in replication efficiency. Interestingly, when combined with
K103N, they substantially augment the level of efavirenz
resistance with little or no adverse effects on replication
efficiency. The mechanism(s) of how V108I and P225H
augment the efavirenz resistance of K103N without directly
affecting resistance themselves has not been studied. However,
crystallographic studies support a role for K103N in stabilizing
the closed form of the NNRTI binding pocket (Hsiou et al.,
2001). Thus, V108I and P225H may further augment K103N's
ability to stabilize the closed form of the NNRTI binding
pocket. In contrast to V108I and P225H, the augmented
resistance conferred by the addition of L100I to K103N comes
with the cost of a substantial reduction in the replication
efficiency.
Our studies suggest that high levels of drug can overcome
the reduced fitness of K103N + L100I. This finding contrasts
with our previous studies of G190S, in which we were unable to
identify a concentration of efavirenz at which the less-fit, more
drug-resistant G190S mutant could overgrow the K103N
mutant (Wang et al., 2006). Taken together, these studies
suggest that minor increases in drug resistance are not sufficient
to overcome moderate reductions in replication efficiency, but
that larger increases in drug resistance, such as the 30-fold
difference in resistance between K103N + L100I and
K103N + V108I, may allow selection for a mutant with
reduced replication efficiency in the presence of drug. Thus, it is
possible that high efavirenz concentrations could account for
the selection of K103N + L100I in some patients.
Since the degree of drug resistance as measured by standard
drug susceptibility assays is similar for K103N and L100I, we
had originally expected that L100I would be substantially less
fit than K103N. Growth competition assays in the absence of
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in the presence of efavirenz demonstrated that L100I is more
susceptible to efavirenz than K103N. This finding suggests that
competition experiments can provide supplemental information
on the susceptibilities of drug-resistant variants to that provided
by standard drug susceptibility assays and may thus lead to a
more complete identification of mutations that contribute to
drug resistance. An alternative explanation for the low
frequency of L100I in clinical isolates is that it has a deficit in
replication fitness not detected by our studies of replication in a
T cell line.
We found that the L74Vmutation compensates for the fitness
impairment of K103N + L100I. It is interesting that an
association between L74V and K103N + L100I was observed
in two clinical studies (Ait-Khaled et al., 2003; Demeter et al.,
2004), suggesting that this combination may be favored because
of the improved replication efficiency of the triple mutant. This
hypothesis is further supported by the observation in one study
that L74V could be selected for in the absence of concomitant
nucleoside therapy (Demeter et al., 2004). Other investigators
have observed that L74V can be selected for in vitro by an
NNRTI alone (Kleim et al., 1996) and have shown that L74V
improves the replication efficiency of a number of mutants at
codon 190 (Huang et al., 2003). Our studies indicate that the
beneficial effect of L74V on the replication efficiency of
NNRTI-resistant mutants is not limited to those at codon 190.
The interaction between L74V and these NNRTI resistance
mutations is just one example of the interplay that occurs
between nucleoside analogs and NNRTIs. For example, the
NNRTI-resistant mutants L100I and Y181C each sensitize HIV-
1 to the nucleoside analog zidovudine (AZT) (Byrnes et al.,
1994; Larder, 1992, 1994). The Y181C mutation sensitizes to
AZT by reducing nucleoside excision (Selmi et al., 2003). In
addition, several nucleoside analog mutations can result in
efavirenz hypersusceptibility (Shulman et al., 2001, 2004). One
implication of these findings is that the choice of which
nucleoside analogs are given with an NNRTI may influence the
development of NNRTI resistance. These mutation interactions
are the most likely explanation for the observation that
concomitant therapy with AZT prevents the emergence of
Y181C during therapy with the NNRTI nevirapine (Richman et
al., 1994). These findings suggest that other nucleoside
resistance mutations, particularly thymidine analog mutations
that confer resistance to AZT, may also affect the replication
fitness of NNRTI-resistant mutants. Further studies of potential
interactions between NNRTI and nucleoside analog resistance
mutations are underway in our laboratory.
The mechanisms underlying the fitness impairment of
K103N + L100I and compensation by L74V are unknown.
The NNRTI resistance mutations V106A, G190A, G190S, and
P236L have no effects on DNA polymerization from a DNA
primer but do reduce rates of RNase H cleavage (Archer et al.,
2000; Gerondelis et al., 1999; Wang et al., 2006). The G190S
and G190A mutants also reduce priming of DNA synthesis
from tRNALys, 3 (Wang et al., 2006). The G190E mutant,
which has a much greater impairment in replication, reduces
both DNA polymerization and RNase H cleavage, and theaddition of L74V improves both these biochemical functions
(Boyer et al., 1998). Studies of reverse transcriptase
polymerase and RNase H function for the K103N + L100I
and K103N + L100I +L74V mutants should add to our
understanding of the biochemical mechanisms underlying
fitness impairments and the virus' ability to correct them.
In summary, our data, using site-directed mutants of a
laboratory strain, suggest that fitness differences in addition to
relative drug resistance can explain the reported frequencies of
resistance mutations during clinical failure of efavirenz-based
therapies, and that growth competition experiments may be
better able to detect relative drug resistance than standard
susceptibility assays. In our studies, L74V compensates for the
K103N + L100I fitness impairment, and this may account for its
preferential selection in combination with this NNRTI-resistant
variant in clinical samples. Further studies are needed to deli-
neate the clinical relevance of compensatory mutations on the
evolution of drug resistance mutations in patients and to describe
the biochemical mechanisms underlying this compensation.
Materials and methods
Reagents and cell lines
The following reagent was obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS,
National Institute of Allergy and Infectious Diseases: the
infectious HIV-1 molecular clone pNL4-3 from Malcolm
Martin. Oligonucleotides were purchased from Oligos Etc
(Wilsonville, OR). Efavirenz was obtained from Dupont
Pharmaceuticals (50 mg/10 ml of DMSO, stored at −20 °C).
The 293 and H9 cell lines were obtained from ATCC (Manassa,
VA). 293 cells were grown in DMEM (Life Technologies,
Gaithersburg, MD) with 10% fetal bovine serum, 100 U/ml
penicillin, 100 U/ml streptomycin, and 2 mM glutamine. H9
cells were grown in RPMI 1640 (ATCC) with 20% fetal bovine
serum, 100 U/ml penicillin, 100 U/ml streptomycin. Both cell
lines were incubated in 5% CO2 at 37 °C.
Site-directed mutagenesis
The L100I, K103N, V108I, P225H, K103N + L100I,
K103N + V108I, K103N + P225H, K103N + L100I +L74V
mutations were each introduced into the vector pRHA1
(Gerondelis et al., 1999), which contains a 4.1-kb region of
pNL4-3 flanked by the SphI and EcoRI restriction sites, using
the QuikChange site-directed mutagenesis kit (Stratagene, La
Jolla, CA). The pol region of HIV-1 containing the relevant
mutations was subcloned from pRHA-1 into pNL4-3 using
ApaI and AgeI. Individual clones of each mutant were isolated
and sequenced to verify the integrity of the cloning sites, the
presence of the appropriate reverse transcriptase resistance
mutation(s), and the absence of spurious mutations. We also
utilized a previously characterized clone of pNL4-3 containing
the delavirdine resistance mutation P236L for comparison
(Gerondelis et al., 1999). 293 cells were transiently transfected
with each pNL4-3 mutant construct using lipofection
191C.E. Koval et al. / Virology 353 (2006) 184–192(SuperFect; Qiagen, Santa Clarita, CA). Infections were
performed in triplicate. Cell-free supernatants were harvested
and assayed for p24 antigen content on day 3. At least two
independently generated virus stocks were used in separate
experiments with similar results.
Efavirenz susceptibility assays
We measured the efavirenz susceptibilities of selected
mutants using a modification of the ACTG-DoD consensus
assay (Japour et al., 1993). Virus stocks were titered in H9 cells.
4 × 106 H9 cells were infected with 4000 TCID50 of virus for
one hour at 37 °C, 5% CO2. 2 × 10
5 cells were then incubated in
a volume of 200 μl medium alone or with escalating
concentrations of efavirenz (range 0.5–100 nM, final concen-
tration). Virus growth at day 7 was determined by p24 ELISA,
and IC50 was calculated using the median effect equation (Chou
and Talalay, 1984) (KaleidaGraph 3.51, Synergy Software).
Growth competition assays for relative fitness of wild-type and
efavirenz-resistant mutants of HIV-1
The relative replication fitness of efavirenz-resistant mutants
of NL4-3 was measured using growth competition experiments
in H9 cells. H9 cells (2.5 × 106) were infected with a pair of
virus stocks at a total of 50–200 ng p24 per competition
(estimated MOI < 0.005, data not shown), in a final volume of
2 ml at 37 °C in 5% CO2 for 1 h. Cells were then washed and
resuspended in 5 ml H9 medium (or in 5 ml of H9 medium
containing the specified concentration of efavirenz). After
7 days (1 passage), 1 ml of culture supernatant was used to
infect an additional 2.5 × 106 H9 cells. Cultured cells (2.5 ml)
were harvested and pelleted at days 3 or 4, 7, 11, and 14. For a
subset of experiments, a third passage was performed, and
cultured cells were harvested at day 21. Genomic DNA was
harvested from cell pellets using the QIAamp DNA Blood Mini
kit (Qiagen). A region of the pol gene encompassing reverse
transcriptase codons 74, 100, 103, 108, and 225 was amplified
using PCR (Platinum Taq High Fidelity; Invitrogen) and the
following primers: RT18 (5′-GGA AAC CAA AAATGATAG
GGG GAA TTG GAG G-3′; and RT21 (5′-CTG TAT TTC
TGC TAT TAA GTC TTT TGATGG G-3′). Cycling conditions
were those recommended by the manufacturer, using an
annealing temperature of 55 °C. Direct sequencing of PCR
products was performed using BigDye version 3.1 fluorescent-
labeled terminators and AmpliTaq (Applied Biosystems). The
relative prevalence of mutant variants at each passage was
quantitated by averaging the relative peak heights using sense
and antisense sequencing primers. Each growth competition
experiment between a given pair of mutants was performed in
duplicate or triplicate.
Clonal analysis
To determine the accuracy of peak heights in quantifying the
relative proportions of mutants present at each time point, PCR
products generated at each time point were cloned into a vector(TOPO-TA, Invitrogen), transformed into MAX Efficiency
DH5a cells (Invitrogen) and grown. Twenty-four sequential
clonal sequences were obtained from each selected time point,
and the relative proportion of each mutant on clonal analysis
was compared to the peak heights reported from direct sequence
analysis of the same PCR product. Results were obtained from
each method without knowledge of results obtained using the
other method.
Calculations of relative fitness
To quantify relative fitness, the proportions of each mutant
at the relevant time points and the fitness difference (1 + the
selection coefficient, s) were determined, according to the
method of Holland et al., where s = ln[(Mt /M0) /(Rt /R0)] /t, t is
the time after co-infection, Rt is the proportion of reference
strain at time t, Mt is the proportion of mutant at time t, R0 is
the proportion of reference strain at time 0, M0 is the
proportion of mutant at time 0 (Holland et al., 1991). Relative
fitness values are reported as (1 + s), compared to the
reference strain's designated value of 1. The value (1 + s) is
also analogous to the log relative fitness, described in a recent
evaluation of different methods to quantify relative fitness
(Wu et al., 2006). For selected competitions fitness was also
calculated using the method of Maree and coworkers, which
incorporates the fold expansion of virus over time, such that
s = ln[(Mt /M0) /(Rt /R0)] /[ln(Wt /W0) + dt], where Wt is the p24
content of reference (usually wild type) virus at time t, W0 is
the p24 content of reference (usually wild type) virus at time
0, d is the half-life of productively infected cells and is
estimated to be 0.5 (Maree et al., 2000). This parameter has
also been recently referred to as the production rate ratio (Wu
et al., 2006). Since relative fitness values did not differ
substantially between the two methods, we report our fitness
values using the method of Holland.
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